Recent Advances in Biomedicine for Cancer Immunotherapy and Harnessing the Tumor Microenvironment

Dear Colleagues,

Immunotherapy is coming to the forefront of precise cancer treatments. Cancer immunotherapy, which includes chimeric antigen receptor T-cell therapy, monoclonal antibody therapy, and immune checkpoint inhibitor therapy, has achieved remarkable results. However, cancer immunotherapy is only effective for some patients, with low response rates and immune-related adverse events. In this decade of rapid development, the combination of biomedicine and cancer immunotherapy has contributed to the future of cancer treatment with precision medicine. The addition of nanomaterials reduces the occurrence of adverse events and promotes the activity of antigen-presenting cells and cytotoxic T cells at the tumor site. Simultaneously, nanodrug delivery systems have played an important role in increasing the antitumor efficacy of various treatments and have been increasingly utilized for synergistic immunotherapy to further enhance the immunogenicity of tumors. Specifically, they can promote the infiltration of immune cells within the tumors and create an environment that is more sensitive to immunotherapy, particularly in solid tumors, by accelerating tumor accumulation and permeability.

In this Special Issue, we invite the submission of papers that study recent strategies in the field of biomedicine for advancing cancer immunotherapy and harnessing the tumor microenvironment.

In this Special Issue, original research articles and reviews are welcome. Research topics may include (but are not limited to) pre-clinical and clinical studies that investigate the various aspects of immunotherapy, as well as those that study the tumor microenvironment in the context of biomedicine.

Dr. Waqas Nawaz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nanotechnology
• biomedicine
• immunotherapy
• cancer
• tumor microenvironment
• tumor biology
• T-cell tumor